Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans.
The mechanism underlying hypertriglyceridemia-associated insulin resistance in humans remains poorly understood. It has been proposed that hypertriglyceridemia only produces insulin resistance when associated with an increased lipid delivery to muscle. Accordingly, hypertriglyceridemia secondary to a decreased clearance of triglyceride-rich particles should not cause insulin resistance. To verify this hypothesis, we assessed whole body and adipose tissue insulin sensitivity in 15 healthy male volunteers before and after a 5-day administration of isotretinoin (1 mg/kg/d), a vitamin A derivative that decreases the clearance of triglyceride-rich particles. Whole body insulin-mediated glucose disposal (6,6 (2)H(2)glucose), glucose oxidation (indirect calorimetry), lipolysis ((2)H(5) glycerol), and subcutaneous adipose lipolysis (microdialysis) were evaluated during a 3-step hyperinsulinemic euglycemic clamp. Isotretinoin increased plasma triglyceride from 0.97 +/- 0.15 to 1.30 +/- 0.22 mmol/L (P <.02), but did not change whole body insulin-mediated glucose disposal and lipolysis. These observations are consistent with an isotretinoin-induced inhibition of very-low-density lipoprotein (VLDL)-triglyceride clearance. The suppression of endogenous glucose production and the reduction in subcutaneous adipose glycerol concentrations by insulin remained equally unaffected after isotretinoin administration. We conclude that the impaired clearance of triglyceride-rich particles secondary to a 5-day isotretinoin administration does not impair insulin-mediated antilipolysis or glucose disposal. The data support the concept that hypertriglyceridemia-associated insulin resistance develops primarily when triglyceride production is increased.
Stoll
Delphine
D
Institute of Physiology, University of Lausanne School of Medicine, Switzerland.
Binnert
Christophe
C
Mooser
Vincent
V
Tappy
Luc
L
D000273:Adipose Tissue / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002153:Calorimetry, Indirect; D003903:Deuterium; D004837:Epinephrine; D005215:Fasting; D015309:Glucose Clamp Technique; D005990:Glycerol / Q000032:analysis / Q000097:blood; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications; D007328:Insulin / Q000097:blood / Q000494:pharmacology; D007333:Insulin Resistance; D015474:Isotretinoin / Q000008:administration & dosage*; D007700:Kinetics; D008066:Lipolysis / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D017551:Microdialysis; D010084:Oxidation-Reduction; D014280:Triglycerides / Q000096:biosynthesis / Q000097:blood*
D001786:Blood Glucose; D007328:Insulin; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D003903:Deuterium; D015474:Isotretinoin; D005990:Glycerol; D004837:Epinephrine